Skip to content

Construction of a Diagnosis and Treatment System for Allergic Rhinitis-Asthma Syndrome (ARAS) Based on Zang-Xiang Theory and Optimization of Traditional Chinese Medicine Prevention and Treatment Strategies: A Cohort Study on the Efficacy of Winter Disease Summer Treatment Herbal Patch Application 'Xia Jie Shu Fei Pian' in the Remission Phase of CARAS

Construction of a diagnosis and treatment system for allergic rhinitis-asthma syndrome based on Zang-Xiang theory and optimization of preventive and therapeutic strategies in traditional Chinese medicine.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002519
Enrollment
Unknown
Registered
2025-12-24
Start date
2025-09-13
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinitis-Asthma Syndrome

Interventions

Control Group:None
Patch Application Group:The internal moxibustion therapy plan of Zhejiang Provincial Hospital of Traditional Chinese Medicine involves grinding the herbal medicine into powder, mixing it with ginger j

Sponsors

Zhejiang University of Traditional Chinese Medicine First Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. Patients who meet the diagnostic criteria of both traditional Chinese and Western medicine for CARAS and are currently in the remission phase; 2.No restriction on gender, aged 18 to 75 years; 3.Voluntarily participate in this clinical trial, voluntarily sign the informed consent form, and are willing to follow the research protocol.

Exclusion criteria

Exclusion criteria: 1. Not meeting the eligibility criteria requirements; 2. Patients suffering from severe cardiovascular, cerebrovascular, hepatic, renal, or hematopoietic system diseases, or patients with severe primary diseases and mental illness; 3. Patients with a history of skin allergies or allergies to known components of the drug; 4. Patients with incomplete data affecting the assessment of efficacy or safety; 5. Patients with conditions unsuitable for application or other severe complications; 6. Patients unwilling to continue clinical observation during the application period or unable to undergo long-term follow-up; 7. Patients currently participating in other clinical trials of drugs.

Design outcomes

Primary

MeasureTime frame
The proportion of CARAS patients experiencing acute exacerbations of rhinitis or asthma within 1 year.;

Secondary

MeasureTime frame
TCM Syndrome Score Improvement Rate;

Countries

China

Contacts

Public ContactZhang Hong

Zhejiang Provincial Hospital of Traditional Chinese Medicine (Affiliated First Hospital of Zhejiang University of Traditional Chinese Medicine)

hz.zhanghong@aliyun.com13588420208

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026